Cargando…

Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study

Use of doravirine (DOR), a new nonnucleoside reverse-transcriptase inhibitors recently approved for HIV treatment, is still unclear in clinical practice and real-life data are scarce. We retrospectively investigated the rationale for switching people with HIV to DOR-containing/-based regimens in a r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mazzitelli, Maria, Antoni, Melania Degli, Castelli, Francesco, Ripamonti, Diego, Zuglian, Gianluca, Lapadula, Giuseppe, Fabbiani, Massimiliano, Ferraresi, Alice, Putaggio, Cristina, Cattelan, Anna Maria, Quiros-Roldan, Eugenia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333545/ https://www.ncbi.nlm.nih.gov/pubmed/35905209 http://dx.doi.org/10.1097/MD.0000000000029855

Ejemplares similares

Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis
por: Mazzitelli, Maria, et al.
Publicado: (2021)

Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model
por: Zizioli, Daniela, et al.
Publicado: (2023)

Non-neutralizing antibodies: Deleterious or propitious during SARS-CoV-2 infection?
por: Zanella, Isabella, et al.
Publicado: (2022)

An HIV elite controller patient carrying the homozygous H63D variant in the homeostatic iron regulator gene: A case report
por: Zanella, Isabella, et al.
Publicado: (2021)

Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study
por: Gotti, Daria, et al.
Publicado: (2014)

Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review
por: Tiecco, Giorgio, et al.
Publicado: (2022)

Cabotegravir Exposure of Zebrafish (Danio rerio) Embryos Impacts on Neurodevelopment and Behavior
por: Zizioli, Daniela, et al.
Publicado: (2023)

Syphilis Infections, Reinfections and Serological Response in a Large Italian Sexually Transmitted Disease Centre: A Monocentric Retrospective Study
por: Marchese, Valentina, et al.
Publicado: (2022)

Monkeypox, a Literature Review: What Is New and Where Does This concerning Virus Come From?
por: Tiecco, Giorgio, et al.
Publicado: (2022)

Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives
por: Quiros-Roldan, Eugenia, et al.
Publicado: (2021)

Omicron BA.2 Lineage, the “Stealth” Variant: Is It Truly a Silent Epidemic? A Literature Review
por: Tiecco, Giorgio, et al.
Publicado: (2022)

The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study
por: Bertuccio, Paola, et al.
Publicado: (2023)

A 2021 Update on Syphilis: Taking Stock from Pathogenesis to Vaccines
por: Tiecco, Giorgio, et al.
Publicado: (2021)

Explorative study regarding influenza vaccine hesitancy among HIV-infected patients
por: Marchese, Valentina, et al.
Publicado: (2022)

Decrease in new diagnosis of HIV/AIDS in the two years period 2019-2020: Impact of COVID-19 pandemic
por: Quiros-Roldan, Eugenia, et al.
Publicado: (2021)

An exploratory pilot study on the involvement of APOE, HFE, C9ORF72 variants and comorbidities in neurocognitive and physical performance in a group of HIV-infected people
por: Zanella, Isabella, et al.
Publicado: (2022)

Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA
por: Mazzitelli, Maria, et al.
Publicado: (2022)

The importance of SHBG and calculated free testosterone for the diagnosis of symptomatic hypogonadism in HIV-infected men: a single-centre real-life experience
por: Pezzaioli, Letizia Chiara, et al.
Publicado: (2020)

Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis
por: Mazzitelli, Maria, et al.
Publicado: (2022)

Doravirine-associated resistance mutations in antiretroviral therapy naïve and experienced adults with HIV-1 subtype C infection in Botswana
por: Bareng, Ontlametse T., et al.
Publicado: (2022)

Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
por: Maggi, Paolo, et al.
Publicado: (2023)

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
por: Greaves, Wayne, et al.
Publicado: (2019)

Immunological Evolution of a Cohort of HIV-2 Infected Patients: Peculiarities of an Underestimated Infection
por: Fumarola, Benedetta, et al.
Publicado: (2022)

Characteristics of the population with mild COVID-19 symptoms eligible for early treatment attended in a single center in Northern Italy
por: Magro, Paola, et al.
Publicado: (2023)

Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV
por: Mazzitelli, Maria, et al.
Publicado: (2023)

Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report
por: Zuglian, G., et al.
Publicado: (2019)

Changes in weight and BMI with first-line doravirine-based therapy
por: Orkin, Chloe, et al.
Publicado: (2021)

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen
por: Iannone, Valentina, et al.
Publicado: (2023)

COVID-19 Pneumonia with Migratory Pattern in Agammaglobulinemic Patients: A Report of Two Cases and Review of Literature
por: Degli Antoni, Melania, et al.
Publicado: (2023)

Comparison between the gold standard DXA with calcaneal quantitative ultrasound based-strategy (QUS) to detect osteoporosis in an HIV infected cohort
por: Quiros Roldan, Eugenia, et al.
Publicado: (2017)

The changing pattern of bacterial and fungal respiratory isolates in patients with and without COVID-19 admitted to intensive care unit
por: Zuglian, Gianluca, et al.
Publicado: (2022)

546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
por: Matthews, Randolph, et al.
Publicado: (2018)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development
por: Martin, Elizabeth Anne, et al.
Publicado: (2020)

Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study
por: Raffetti, Elena, et al.
Publicado: (2015)

Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals
por: Bai, Francesca, et al.
Publicado: (2023)

Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study
por: Quiros-Roldan, Eugenia, et al.
Publicado: (2016)

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre
por: Borghetti, Alberto, et al.
Publicado: (2014)

Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
por: Rock, Alexander E, et al.
Publicado: (2020)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_panc41ieslmsi4vbc22jdjfl0e